Editorial Comment

No AccessJournal of UrologyAdult Urology1 May 2022Editorial CommentThis article comments on the following:Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy Abraham Morgentaler Abraham MorgentalerAbraham Morgentaler Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002384.01AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Editorial Comment." The Journal of Urology, 207(5), p. 1028 References 1. : Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clinic Proc 2015; 90: 224. Google Scholar 2. : Testosterone therapy in men with biochemical recurrence and metastatic prostate cancer: initial observations. Androg Clin Res Ther 2021; 2: 121. Google Scholar © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal of Urology3 Jan 2022Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy Volume 207Issue 5May 2022Page: 1028-1028 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Abraham Morgentaler Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts More articles by this author Expand All Advertisement PDF downloadLoading ...